Azmasol

Azmasol ( 200) Inhaler

SKU: M18031

GEN Name: Salbutamol BP
Per Pieces
195.00 BDT

Description: Azmasol® HFA inhaler is an environment friendly, CFC-free inhaler. It contains Salbutamol BP (as sulfate) as the active ingredient which is a ß2- adrenoceptor agonist used in the treatment of asthma and other forms of diffuse reversible airways obstruction. Indication: Azmasol® HFA (Salbutamol) inhaler is indicated for the treatment…

Quantity:
-
+

Description: Azmasol® HFA inhaler is an environment friendly, CFC-free inhaler. It contains Salbutamol BP (as sulfate) as the active ingredient which is a ß2- adrenoceptor agonist used in the treatment of asthma and other forms of diffuse reversible airways obstruction. Indication: Azmasol® HFA (Salbutamol) inhaler is indicated for the treatment and prophylaxis of bronchial asthma and for the treatment of reversible airways obstruction associated with bronchitis and emphysema. Azmasol® HFA (Salbutamol) inhaler may be used to relieve attacks of acute dyspnoea and may also be taken prophylactically before exertion or to prevent exercise-induced asthma. It is suitable for treating bronchospasm in patients with coexisting heart disease or hypertension, including those taking beta blockers, because of its selective action on the bronchial receptors and lack of effects on the cardiovascular system. Salbutamol is a sympathomimetic agent which has a highly selective action on beta adrenergic receptors in bronchial muscle. At therapeutic levels, it has little effect on cardiac receptors. Dosage: Adults: For the relief of acute bronchospasm and for managing intermittent episodes of asthma: one or two inhalation as a single dose; for chronic maintenance or prophylactic therapy: two inhalations three or four times daily; for prevention of exercise induced bronchospasm : two inhalations before exertion. Children: for the relief of acute bronchospasm, management of episodic asthma and for prevention of exercise induced bronchospasm: one inhalation; for routine maintenance and prophylaxis: one inhalation three or four times daily, increasing if necessary to two inhalations three or four times daily. Elderly: The dosage is the same as that for adults. Contraindications: Although intravenous Salbutamol, and occasionally Salbutamol tablets, are used in the management of premature labour uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage or toxaemia of pregnancy, Salbutamol inhaler preparations are not appropriate for managing premature labour. Salbutamol preparation should not be used for threatened abortion during the first or second trimesters of pregnancy. Salbuatmol inhaler is contraindicated in patients with a history of hypersensitivity to any of its components. Precautions: In the event of previously effective dose of Salbuatmol inhaler failing to give relief for at least three hours, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken. Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. Side Effects: Mild tremor and headache have been rarely reported. These usually disappear with continuous treatment. There have been very rare reports of transient muscle cramp. Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse have been reported very rarely. As with other inhalation therapy, the potential for paradoxical bronchospasm should be kept in mind. If it occurs, the preparation should be discontinued immediately and alternative therapy should be instituted. Pharmaceutical Precautions: Pressurised canister, do not puncture, break or incinerate even when apparently empty. Avoid storage in direct sunlight or heat. Store below 30°C. Keep away from eyes. Keep away from children. Commercial Pack: Azmasol® HFA is available in two different packs containing 200 & 300 metered doses, each puff containing 100 mcg of Salbutamol BP (as sulfate). References: 1. The Montreal Protocol 2. FDA guidance documents on MDI retrieved from FDA website 3. www.qvar.com 4. Clin Ther. 2000 Feb; 22(2):237-47 Patients don’t need to shake Decomit HFA before using because it is formulated as solution with advanced HFA technology. Patients need to shake Azmasol HFA before using as it remains in suspension as previous Azmasol. Azmasol® HFA (Salbutamol sulfate HFA inhalation aerosol) Decomit ® HFA (Beclomethasone dipropionate HFA inhalation aerosol) First time in Bangladesh BEXIMCO PHARMACEUTICALS LTD. DHAKA, BANGLADESH ® Azmasol HFA & Decomit HFA are the registered trademarks of Beximco Pharmaceuticals Ltd.